Pre-ISDS meeting of the IEC
Wednesday, November 16, 2016
Category: IEC Events (for everyone)

The day of the opening of the Inflammatory Skin Disease Summit (Nov 16-19, 2016) at the New York Academy of Medicine, New York, NY, Room 20 – 2nd floor, the International Eczema Council presented an educational session on topical and systematic therapies. Featuring a morning spotlight on real-life adult and pediatric patients and parents, the presentation was be accompanied by roundtable discussions with patients, caregivers and physicians. The presentation continued in the early afternoon with lectures on novel AD treatments (topical and systemic).

10:00 – 10:10 am

Welcome and Introduction to the IEC

10:10 – 11:40 am

The Patient Perspective

The impact of AD on the everyday lives of patients and families is profound. Five patient/parent speakers (three adults diagnosed with AD and the parents of two children with AD) will share their experiences of living with AD, and how intervention has changed the quality of their lives.

11:40 am – 12:00 pm

Panel Discussion and Questions: The Patient Perspective

12:00 – 12:40 pm

Lunch (box lunches provided)

12:40 – 1:00 pm

Comorbidities in Children and Adults with AD (Dr. Amy Paller)

Although AD has long been known to be associated with allergic disorders (allergic rhinitis and asthma), there is increasing evidence of other comorbidities.

Novel Developments in Atopic Dermatitis Treatments

1:00 – 1:20 pm

Biologics (Dr. Lisa Beck)

Although many biologic agents are available to treat psoriasis, only recently have biologics been evaluated for atopic dermatitis. Many of these target components of a Type 2 immune response. The hope is that these targeted therapies will improve the immune dysregulation, skin barrier dysfunction and chronic Staphylococcal aureus colonization commonly observed with AD, with less off-target effects.

1:20 – 1:40 pm

Oral Therapies (Dr. Emma Guttman)

While several immunosuppressants are approved for psoriasis, only oral prednisone is currently approved systemically for AD. This creates a large, unmet need for systemic treatments. Several oral compounds targeting JAK-STAT, Th2, PDE4, H4, and other pathways are under development aiming to provide safer, long-term alternatives.

1:40 – 2:00 pm

Topical Therapies (Dr. Lawrence Eichenfield)

Topical corticosteroids have long been the mainstay of treatment for AD. Topical calcineurin inhibitors came on the scene more than ten years ago and provided the first alternative to topical steroids. Now, other anti-inflammatory, non-steroidal agents are emerging, the most advanced being phosphodiesterase 4 (PDE4) inhibitors.

2:00 – 2:30 pm

Panel Discussion and Questions